Floatz logo

Midostaurin

Aggressive Systemic Mastocytosis

Jason Robert GotlibSmall moleculePhase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Aggressive Systemic Mastocytosis cohort.

Asset / SponsorPhaseRating
Avapritinib
Blueprint Medicines Corporation
Phase 2BB
Brentuximab Vedotin
Jason Robert Gotlib
Phase 2B
Ibrutinib
Jason Robert Gotlib
Phase 2CCC
Bezuclastinib
Cogent Biosciences, Inc.
Phase 2CCC
mgd024
MacroGenics
Phase 1NR

Same molecule, other indications

Midostaurin is also rated in:

acute myeloid leukemia by FAB classificationDormant
B
Indicative ·
63 / 100
View asset →
acute myeloid leukemiaDormant
B
Indicative ·
62 / 100
View asset →
myelodysplastic syndrome with excess blasts-2Dormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →